HumanFirst, Formerly Elektra Labs, Helps 22 of the 25 Leading Pharma Companies Safely, Effectively, and Equitably Support Clinical Trials at Home
With the Help of $12 Million in Series a Funding, the Newly Renamed Company Is Expanding Offerings as Decentralized Clinical Trials and Virtual Care Have Grown 5x in the Past Year.
HumanFirst, the experts in decentralized clinical trials and distributed, virtual healthcare, announced the closing of a Series A fundraise and a name change to reflect the company’s focus on enabling healthcare operations at home. The $12M Series A round was preempted by seed investors Maverick Ventures (lead), Lux Capital, Arkitekt Ventures, Boost VC, SV Angel, and Village Global. Threshold Ventures and an additional 30+ angel investors joined this group for the Series A fundraise.
This Series A investment brings HumanFirst’s total funding to $15M since the company’s inception. In that time, 22 of the top 25 pharmaceutical companies by revenue have used the HumanFirst platform to evaluate and enable the deployment of technology products.
Recommended AI News: Daily AI Roundup: The 5 Coolest Things on Earth Today
HumanFirst launched its Atlas platform in 2019 to help organizations safely, effectively, and equitably deploy connected products for clinical trials and remote patient monitoring. Since that time, the company has worked with nearly all of the top global pharmaceutical companies and has spearheaded the creation of ‘The Digital Measures Playbook’ of open-access best practices for capturing patient signals and decreasing risk when deploying, managing, and monitoring connected products in home-based settings. With the addition of Series A funding, HumanFirst will expand to enable an API-led operational infrastructure related to decentralized trials and distributed care.
“Healthcare is coming home, giving individuals more agency over their health and wellness. We’ve changed our name to reflect this important shift,” explained HumanFirst CEO Andy Coravos. “We need to ensure that home-based operations are as reliable and trustworthy as those within the hospital or the research site. HumanFirst is building the control center to make this happen.” The additional capital will go toward increasing HumanFirst’s footprint as the infrastructure layer to support home-focused clinical operations ranging from sensors to in-home visits, testing, and more.
“Health technology innovation has always moved faster than the guardrails necessary to securely, efficiently, and thoughtfully support it,” said Maverick Ventures Managing Director Ambar Bhattacharyya. “HumanFirst is a necessary company in ensuring we’re on path for the future of healthcare at home, which is why we are thrilled to double down on our investment and lead the Series A round.”
Recommended AI News: Progress Announces Availability of Connectors with AWS Glue in AWS Marketplace